• PP 3: Identity, Control Role, and Evidence Limits

  2026-10-16

  APExBIO identifies PP 3, or 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, as a research use only chemical positioned as a negative control for the Src kinase inhibitor PP 2. The available product record supports its catalog identity, stated physicochemical properties, and intended comparator role, but does not establish an independent molecular mechanism, Src selectivity profile, biological inactivity, or study outcome.

• PP 3: Identity, Control Role, and Evidence Limits

  2026-10-15

  APExBIO identifies PP 3, or 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, as a research use only chemical positioned as a negative control for the Src kinase inhibitor PP 2. The cited product information establishes chemical identity, basic specifications, and intended comparator role, but it does not provide identity-matched primary research, measured kinase selectivity, assay outcomes, or evidence that PP 3 is biologically inert across systems.

• S-Adenosylhomocysteine: Evidence and Scope

  2026-10-15

  A source-limited overview of S-Adenosylhomocysteine (SAH), its reported relationship to SAM-dependent methylation, the SAM/SAH ratio, and the boundaries of the available product evidence.

• Oleic Acid in HIRI Research: What the Evidence Shows

  2026-10-14

  A 2024 preclinical study linked Radix Rehmanniae Praeparata extract with improved hepatic ischemia–reperfusion injury and altered cholesterol metabolism in mice and fatty-acid-loaded hepatocytes. The findings support a model involving AMPK, mTOR, SREBP2, and LXRα, but they do not establish an isolated effect of Oleic Acid, equivalence to a commercial formulation, or clinical benefit.

• ROS, LTCCs and Developing Arteries

  2026-10-14

  A 2025 study examined how NADPH oxidase-derived reactive oxygen species influence contraction in early postnatal rat arteries. Its pharmacological and molecular evidence supports a role for L-type calcium channels downstream of ROS, while providing weaker support for involvement of Rho-kinase, PKC, or Src kinase. The findings are limited by the ex vivo animal model and reliance on inhibitor-based inference.

• What This H5/H7 mRNA Vaccine Study Shows

  2026-10-13

  Wei and colleagues evaluated a bivalent mRNA–lipid nanoparticle vaccine targeting H5N1 and H7N9 hemagglutinin antigens in specific-pathogen-free chickens. The study reports dose-responsive antibody responses, neutralization of homologous viruses and cross-reactivity with heterologous strains, and complete protection in the tested high-dose challenge groups. However, the evidence remains limited to a controlled chicken model and selected viral strains; it does not establish effectiveness in commercial poultry, other species, or humans.

• DHEA in PCOS Research: Evidence and Boundaries

  2026-10-13

  Dehydroepiandrosterone (DHEA) has diverse steroid-signaling and neurobiological associations, but the supplied PCOS study used DHEA to establish a disease model rather than to test DHEA as a treatment. Its principal findings concern Jiao-tai-wan, coptisine, SIRT1, mitochondrial cholesterol handling, and ovarian steroidogenesis in rats and primary theca cells.

• CNQX and cNTS Cardiovascular Signaling

  2026-10-12

  CNQX is a pharmacological neuroscience research tool used to distinguish AMPA/kainate-receptor signaling from other glutamatergic mechanisms. In a 2024 rat study, CNQX-sensitive signaling was not the principal pathway implicated in chemerin-driven cardiovascular responses from the caudal nucleus tractus solitarius, but the result is limited by the study model and by the interpretive limits of receptor antagonism.

• Oleic Acid: Evidence, Scope and Limits

  2026-10-12

  Oleic Acid (C18:1(9Z)) is a context-dependent lipid-signaling molecule rather than a universally protective or harmful agent. The supplied hepatic ischemia–reperfusion study used oleic acid with palmitic acid to model lipid loading in hepatocytes; its therapeutic findings concerned Radix Rehmanniae Praeparata, not oleic acid itself.

• RRP, Oleic Acid, and Hepatic Ischemia–Reperfusion

  2026-10-11

  A source-grounded overview of a 2024 Journal of Ethnopharmacology study examining whether Radix Rehmanniae Praeparata extracts protect against hepatic ischemia–reperfusion injury by restoring hepatocyte lipid handling. The study combines mouse and cell-based models to examine AMPK–mTOR signaling, SCAP–SREBP2-mediated cholesterol synthesis, and LXRα-dependent cholesterol efflux. Oleic Acid, or C18:1(9Z), appears in the supplied summary as part of a lipid-loading model rather than as a therapeutic intervention. The findings support a preclinical mechanistic hypothesis but do not establish clinical efficacy, a single active constituent, or a direct therapeutic role for Oleic Acid.

• Amitriptyline HCl Product Overview

  2026-10-10

  A catalog-level overview of Amitriptyline HCl (SKU B2231), covering its documented identity, listed specifications, conceptual neuropharmacology scope, and the absence of matched paper evidence.

• PP 3: A Control for Causal Inference

  2026-10-09

  1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine provides a focused way to interpret PP 2-sensitive signaling results. This article connects PP 3 control logic with new evidence on redox-dependent vascular contraction while defining the limits of pharmacological attribution.

• O-GlcNAcylation Rewires Wnt-Driven Bone Formation

  2026-10-09

  The reference study identifies O-GlcNAcylation as a mechanistic bridge between Wnt signaling, aerobic glycolysis, and osteoblast-mediated bone formation. Its findings connect Wnt-dependent regulation of GFAT1 and PDK1 to metabolic remodeling, while genetic evidence supports a role for O-GlcNAcylation in bone formation and fracture healing.

• Angiotensin 1/2 (5-7): Evidence and Research Context

  2026-10-08

  Angiotensin 1/2 (5-7), also described as the H2N-Ile-His-Pro-OH peptide, is a short renin–angiotensin system fragment with a distinct evidence profile. Current research supports a hypothesis-generating role in receptor-binding studies, but supplied evidence does not establish independent vasoconstrictor activity, clinical relevance, or a causal role in COVID-19.

• APEX2, TERT Expression, and Human Stem Cells

  2026-10-08

  A 2024 bioRxiv preprint identifies APEX2, but not its paralog APEX1, as a contributor to efficient TERT expression and telomerase activity in human embryonic stem cells. Its results connect APEX2 binding with repetitive DNA near TERT, suggesting a potential relationship between DNA repair at damage-prone repeats and transcriptional control, while leaving the causal mechanism unresolved.

8066 records 1/538 page Next 12345 下5页 Last page